The role of thrombosis in severe pulmonary hypertension

European Respiratory Journal

Volumn 9, Issue 2, 1996, Pages 356-363

  Chaouat, A ^a,b   Weitzenblum, E ^b   Higenbottam, T ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Coagulation; Fibrinolysis; Platelets; Pulmonary hypertension; Pulmonary thrombosis

Indexed keywords

ANTICOAGULANT AGENT; PROSTACYCLIN;

BLOOD CLOTTING; FIBRINOLYSIS; HUMAN; LUNG CIRCULATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; BLOOD PLATELETS; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; PULMONARY EMBOLISM; THROMBIN;

EID: 0030028272     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09020356     Document Type: Review

References (86)

1. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Third edn. Philadelphia, J.B. Lippincott Co. 1994; pp. 3-18.
2. Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8: 37-55.
3. Dahlback B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77: 1-43.
4. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979; 300: 1142-1147.
5. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
6. Loskutoff DJ, Edgington TE. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 1977; 74: 3903-3907.
7. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in out-patients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516.
8. Moser K. Venous thromboembolism: state of the art. Am Rev Respir Dis 1990; 141: 235-249.
9. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60: 16-25.
10. Wagenvoort CA, Mulder PH. Thrombotic lesion in primary plexogenic arteriopathy: similar pathogenesis or complication? Chest 1993; 103: 844-849.
11. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685-692.
12. Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980; 77: 614-625.
13. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-1206.
14. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163-1181.
15. Moser KM, Fedullo PF, Finkbeiner WE, Golden J. Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation 1995; 91: 741-745.
16. Nemerson Y. The tissue factor pathway of blood coagulation. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hematostasis and Thrombosis: Basic Principles and Clinical Practice. Third edn. Philadelphia, J.B. Lippincott Co., 1994; pp. 81-93.
17. Tran TH, Marbet GA, Duckert F. Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet 1985; ii: 413-414.
18. Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet 1985; ii: 414-416.
19. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82: 841-847.
20. Rostagno C, Prisco D, Abbate R, Poggesi L. Pulmonary hypertension associated with long-standing thrombocytosis. Chest 1991; 99: 1303-1305.
21. Rich S, Hart K. Familial pulmonary hypertension in association with an abnormal hemoglobin: insights into the pathogenesis of primary pulmonary hypertension. Chest 1991; 99: 1208-1210.
22. Rich S, Pietra GG, Kieras K, Hart K, Brundage BH. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 1986; 105: 499-502.
23. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a co-factor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
24. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
25. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
26. Reitsma PH, Poort SR, Bernardi F, et al. Protein C deficiency: a database of mutations. Thromb Haemost 1993; 69: 77-84.
27. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73: 712-717.
28. Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104: 236-250.
29. Stern DM, Nawroth PP, Kisiel W, Vehar G, Esmon CT. The binding of factor IXa to cultured bovine aortic endothelial cells: induction of a specific site in the presence of factors VIII and X. J Biol Chem 1985; 260: 6717-6722.
30. Rodgers GM, Greenberg CS, Shuman MA. Characterization of the effects of cultured vascular cells on the activation of blood coagulation. Blood 1983; 61: 1155-1162.
31. Prydz H, Pettersen KS. Synthesis of thromboplastin (tissue factor) by endothelial cells. Haemostasis 1988; 18: 215-223.
32. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53: 231-241.
33. Girma JP, Meyer D, Verweij CL, Pannekoek H, Sixma JJ. Structure-function relationship of human von Willebrand factor. Blood 1987; 70: 605-611.
34. Rabinovitch M, Andrew M, Thom H, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987; 76: 1043-1052.
35. Geggel RL, Carvalho AC, Hoyer LW, Reid LM. Von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987; 135: 294-299.
36. Lopes M, Maeda NY, Aiello VD, Ebaid M, Bydlowski SP. Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 1993; 104: 1455-1460.
37. Lopes AAB, Maeda NY. Abnormal degradation of von Willebrand factor main subunit in pulmonary hypertension. Eur Respir J 1995; 8: 530-536.
38. George JN, Pickett EB, Saucerman S, et al. Platelet surface glycoproteins. J Clin Invest 1986; 78: 340-348.
39. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
40. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324: 1539-1547.
41. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352.
42. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588-5592.
43. Humbert M, Monti G, Brenot F, et al. Serum IL-1, IL-6 and TNF-α in primary pulmonary hypertension. Am J Respir Crit Care Med 1994; 149: A747.
44. Welsh CH, Marlar RA, Hassell KL. Coagulation activation, fibrinolysis and severity of pulmonary hypertension. Am J Respir Crit Care Med 1994; 149: A746.
45. Sakata Y, Okada M, Noro A, Matsuda M. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor-1 on the surface of endothelial cells. J Biol Chem 1988; 263: 1960-1969.
46. Benotti JR, Ockene IS, Alpert JS, Dalen JE. The clinical profile of unresolved pulmonary embolism. Chest 1983; 84: 669-675.
47. Olman MA, Marsh JJ, Lang IM, Moser KM, Binder BR, Schleef RR. Endogenous fibrinolytic system in chronic large vessel thromboembolic pulmonary hypertension. Circulation 1992; 86: 1241-1248.
48. Schulman LL, Grossman BA, Owen J. Platelet activation and fibrinopeptide formation in pulmonary hypertension. Chest 1993; 104: 1690-1693.
49. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; 150: 929-933.
50. Schultze AE, Roth RA. Procoagulant and fibrinolytic properties of bovine endothelial cells treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 1993; 122: 7-15.
51. Schultze AE, Roth RA. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 1993; 121: 129-137.
52. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston: platelet-endothelium interactions. N Engl J Med 1993; 328: 628-635.
53. Heffner JE, Sahn SA, Repine JE. The role of platelets in the adult respiratory distress syndrome: culprits or bystanders? Am Rev Respir Dis 1987; 135: 482-492.
54. Schafer AI, Crawford DD, Gimbrone MA Jr. Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest 1984; 73: 1105-1112.
55. Heffner JE, Repine JE. Platelets. In: Crystal RG, West JB, Barnes PJ, Cherniack NS, Weibel ER, eds. The Lung: Scientific Foundations. New York, Raven press, 1991; pp. 617-630.
56. Merkow L, Kleinerman J. An electron microscopic study of pulmonary vasculitis induced by monocrotaline. Lab Invest 1966; 15: 547-564.
57. Kanai Y, Hori S, Tanaka T, et al. Role of 5-hydroxytriptamine in the progression of monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 1993; 27: 1619-1623.
58. Lee S-L, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994; 266: L46-52.
59. Pitt BR, Weng W, Steve AR, Blakely RD, Reynolds I, Davies P. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. Am J Physiol 1994; 266: L178-186.
60. Pakala R, Willerson JT, Benedict CR. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 1994; 90: 1919-1926.
61. McMahon TJ, Hood JS, Nossaman BD, Kadowik PJ. Analysis of responses to serotonin in the pulmonary vascular bed of the cat. J Appl Physiol 1993; 75: 93-102.
62. Crowley ST, Dempsey EC, Horwik KB, Horwik LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-1918.
63. Herve P, Drouet L, Dosquet C, et al. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med 1990; 89: 117-120.
64. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
65. Atanassoff PG, Weiss BM, Schmid ER, Tomic M. Pulmonary hypertension and dexfenfluramine. Lancet 1992; 339: 436.
66. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537-541.
67. Triplett DA, Brandt JT. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon. Hematol Pathol 1988; 2: 121-143.
68. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366-374.
69. Parke AL, Weinstein RE, Bona RD, Maier DB, Walker FJ. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S. Am J Med 1992; 93: 49-56.
70. Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant N Engl J Med 1986; 314: 1193-1194.
71. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432.
72. Tsakiris DA, Marbet GA, Makris PE, Settas L, Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemost 1989; 61: 175-177.
73. Carreras LO, Vermylen JG. "Lupus" anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 38-40.
74. Reverter J-C, Tàssies D, Escolar G, et al. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system. Thromb Haemost 1995; 73: 132-137.
75. Petraiuolo W, Bovill E, Hoak J. The lupus anticoagulant stimulates the release of prostacyclin from human endothelial cells. Thromb Res 1988; 50: 847-855.
76. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-344.
77. Butt AY, Cremona G, Wood G, Katayama Y, Higenbottam TW. Anticardiolipin antibodies and pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: A726.
78. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990; 17: 1292-1298.
79. Luchi ME, Asherson RA, Lahita RG. Primary idiopathic pulmonary hypertension complicated by pulmonary arterial thrombosis: association with antiphospholipid antibodies. Arthritis Rheum 1992; 35: 700-705.
80. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
81. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
82. Frank H, Gurtner HP, Kneussl M, Lang I, Mlczoch J. Aminorex-induzierte, plexogene pulmonale Arteriopathie: 25 Jahre danach. Z Kardiol 1993; 82: 568-572.
83. Higenbottam TW, Wheeldon D, Wells FC, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Lancet 1984; i: 1046-1047.
84. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70: 366-370.
85. Barst RJ, Rubin LJ, McGoon MD, Caldwell FJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415.
86. 2) on survival in moderate and severe pulmonary hypertension. Am J Respir Crit Care Med 1994; 149: A748.